EUVIMEDEUVIMED entdecken
Crossref

CDRxAbs: antibody small-molecule conjugates with computationally designed target-binding synergy

Jingzhou Wang, Aiden J Aceves, Nicholas J Friesenhahn, Stephen L Mayo

Protein Engineering, Design and Selection · 2025

DOI: 10.1093/protein/gzaf004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein Engineering, Design and Selection, 2025. Verfasst von Jingzhou Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, United States. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Immunoconjugates, Small Molecule Libraries, Protein Engineering. Die Arbeit nennt 61 Literaturangaben. Gefördert von: Caltech Merkin Institute for Translational Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bioconjugates as therapeutic modalities combine the advantages and offset the disadvantages of their constituent parts to achieve a refined spectrum of action. We combine the concept of bioconjugation with the full atomic simulation capability of computational protein design to define a new class of molecular recognition agents: CDR-extended antibodies, abbreviated as CDRxAbs. A CDRxAb incorporates a covalently attached small molecule into an antibody/target binding interface using computational protein design to create an antibody small-molecule conjugate that binds tighter to the target of the small molecule than the small molecule would alone. CDRxAbs are also expected to increase the target binding specificity of their associated small molecules. In a proof-of-concept study using monomeric streptavidin/biotin pairs at either a nanomolar or micromolar-level initial affinity, we designed nanobody-biotin conjugates that exhibited >20-fold affinity improvement against their protein targets with step-wise optimization of binding kinetics and overall protein stability. The workflow explored through this process promises a novel approach to optimize small-molecule based therapeutics and to explore new chemical and target space for molecular-recognition agents in general.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesImmunoconjugatesSmall Molecule LibrariesProtein EngineeringBiotinStreptavidinHumansProtein Binding

Stichwörter der Autor:innen

Antibody Drug ConjugateAntibody EngineeringCDRxAbComputational DesignProtein Design

Substanzen

BiotinSingle-Domain AntibodiesStreptavidinImmunoconjugatesSmall Molecule Libraries

Autor:innen und Institutionen

  • Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, United States.
  • Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, United States.
  • Merck Research Laboratories, 213 E Grand Ave, South San Francisco, CA 94080, USA.
  • Insight Partners, 1114 Avenue of the Americas, 36th Floor, New York, NY 10036, USA.

Förderung

  • Caltech Merkin Institute for Translational Research

Zitieren

APA

Wang, J., Aceves, A. J., Friesenhahn, N. J., & Mayo, S. L. (2025). CDRxAbs: antibody small-molecule conjugates with computationally designed target-binding synergy. Protein Engineering, Design and Selection. https://doi.org/10.1093/protein/gzaf004

Vancouver

Wang J, Aceves AJ, Friesenhahn NJ, Mayo SL. CDRxAbs: antibody small-molecule conjugates with computationally designed target-binding synergy. Protein Engineering, Design and Selection. 2025. doi:10.1093/protein/gzaf004

BibTeX
@article{Wang2025,
  author = {Wang, Jingzhou and Aceves, Aiden J and Friesenhahn, Nicholas J and Mayo, Stephen L},
  title = {CDRxAbs: antibody small-molecule conjugates with computationally designed target-binding synergy},
  journal = {Protein Engineering, Design and Selection},
  year = {2025},
  doi = {10.1093/protein/gzaf004}
}
Kostenlos starten →